Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2015 August;63(4) > Minerva Cardioangiologica 2015 August;63(4):329-42

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Cardioangiologica 2015 August;63(4):329-42

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Management of cardiogenic shock in the setting of ST-elevation myocardial infarction: controversies and future directions

Kohl L. P. 1, Jones W. S. 1, 2

1 Division of Cardiology, Duke Heart Center, Duke University Medical Center, Durham, NC, USA; 2 Duke Clinical Research Institute, Durham, NC, USA


PDF


The treatment of patients with ST-segment elevation myocardial infarction (STEMI) has changed dramatically since reperfusion therapy has been adopted more commonly, yet 5-10% of patients still develop cardiogenic shock and remain a therapeutic challenge in the setting of STEMI. In this review, we outline the available evidence from randomized controlled trials and registries, including risk factors, diagnostic tools, and various treatments. The main focus of this report is on the currently available treatment options (revascularization, intra-aortic balloon counterpulsation), emerging treatment options (percutaneous hemodynamic support, extracorporeal membrane oxygenation), and ongoing efforts to design systems of care to more efficiently care for these patients.

inizio pagina